Three Drug Makers Answer HRSA’s 340B Contract Pharmacy Letters Defiantly

Lilly, Novartis, and Sanofi sent HRSA defiant responses to its May 17 letters telling the companies that their 340B contract pharmacy policies were illegal.

On May 17, the federal government told six drug companies that their 340B contract pharmacy policies were illegal, and it asked them to provide updates by June 1 on their plans to comply with the law.

At least three of

Read More »

DOJ Says Lilly and Novo Nordisk’s 340B Actions Cost Providers Over $125 Million a Month and Hurt Patients

Lilly and Novo Nordisk's denials of 340B drug discounts when covered entities use contract pharmacies are each causing entities to lose more than $62 million per month on average in 340B program savings, the government says.

Drug manufacturers Eli Lilly and Novo Nordisk’s denials of 340B drug discounts when covered entities use contract pharmacies are causing entities to lose more than a combined total of $125 million per month in 340B program savings, federal filings in

Read More »

CMS Taps Massachusetts Medicaid Director to Run Key Post Impacting 340B Program

Massachusetts Medicaid director Daniel Tsai has been named Director of CMS’s Center for Medicaid and CHIP Services.

The U.S. Centers for Medicare & Medicaid Services (CMS) announced on Monday that Massachusetts’ Medicaid director Daniel Tsai has been named Deputy Administrator of CMS and Director of CMS’s Center for Medicaid and CHIP Services (CMCS). A record 80 million

Read More »

NEWS ANALYSIS: Top Job at HRSA Remains Unfilled as Biden Presidency Enters its Sixth Month

President Biden has yet to select a new leader for the Health Resources and Services Administration, the federal agency responsible for the 340B drug pricing program.

Today is President Biden’s 155th day in office, and he has yet to pick someone to run the U.S. Health Resources and Services Administration (HRSA), the federal agency responsible for the 340B drug pricing program.

This normally might be a

Read More »

Recent Supreme Court Ruling Frees States to Stop PBMs’ 340B Two-Tier Pricing, Health Care Lawyers Say

A recent Supreme Court decision was a big win for 340B providers, K&L Gates partners (left to right) Don Walker, Leah D’Aurora Richardson, and Victoria Hamscho say in a new American Health Law Association paper.

A recent U.S. Supreme Court decision is spurring more states to enact laws banning pharmacy benefit managers (PBMs) from reimbursing 340B pharmacies less for prescription drugs than non-340B providers, health care lawyers say in a new paper.

According to the

Read More »

340B Report Publisher and CEO Examines Four Burning Questions in Contract Pharmacy Standoff

In his latest column for Omnicell, 340B Report Publisher and CEO Ted Slafsky ponders four questions that need to be addressed in the contract pharmacy standoff.

In his latest column for Omnicell, 340B Report Publisher and CEO Ted Slafsky ponders four burning questions as we approach the first anniversary of drug manufacturers stopping or placing restrictions on 340B drug discounts in the contract pharmacy setting.

Read More »

HRSA’s Order for 340B is a Win for Rural Accountable Care

SPONSORED CONTENT by Dr. LeeAnn Scheer, Caravan Health

Safety net facilities are celebrating the May 17 HRSA letters to six drug manufacturers affirming they must provide drugs to covered entities through their contract pharmacies at the 340B ceiling price. This decision will help these facilities, many of them rural, stretch this federal program to improve their financial sustainability and continue to provide excellent care

Read More »

News Alert: Becerra Puts His Imprint On Long-Awaited 340B Dispute Resolution Board

HHS Secretary Xavier Becerra made appointments today to the 340B administrative dispute resolution board. | Shutterstock

U.S. Health and Human Services (HHS) Secretary Xavier Becerra this morning announced his six appointees to the long-awaited 340B administrative dispute resolution (ADR) board.

The move will be welcomed by the 340B provider community, which has pushed for the creation

Read More »

Pharma’s 340B Contract Pharmacy Limits Are Costing Providers $3.2 Billion a Year, DOJ Tells Court

Covered entities' monthly 340B savings on Sanofi products dropped from $54.2 million just before the company limited discounts on drugs shipped to contract pharmacies to about $5 million within two months, federal lawyers told a judge last week.

Hospitals, health centers, and clinics are losing a projected $3.2 billion a year in 340B program savings due to six drug manufacturers’ denials of 340B pricing on drugs shipped to contract pharmacies, the federal government said in a court filing

Read More »

DOJ and AstraZeneca Far Apart on How Company’s Lawsuit Should Proceed

AstraZeneca and the federal government are miles apart on what a federal judge should do next in the company's 340B contract pharmacy lawsuit.

Drug manufacturer AstraZeneca and the federal government are miles apart on what a federal judge should do next after ruling last week that the government had no basis for stating in December that the 340B statute unambiguously requires manufacturers to

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report